Heparin refers to the anticoagulant which is stored in the mast cells and secreted at the injury site and is intended towards prevention of blood clots. Heparin, primarily is derived from pig intestine or bovine (cow) lungs, but after crisis of bovine heparin in 1980s, porcine heparin is widely adopted across the globe. Heparin is widely applied in thrombic and cardiovascular disorders, surgery and kidney dialysis and anticoagulant coatings. Scalar Market research anticipates that the markets for Heparin to grow exponentially by the end of 2022 as majority of the players are developing generic formulations for blood coagulations and other new therapeutic areas.

Heparin Market Dynamics

Heparin market exhibits significant growth and value due to growing population of VTE (venous thromboembolism), obesity, declining imports from china and growing adoption of new oral anticoagulants. In addition to this, the possibility of regulatory approval of synthetic heparin and comeback of bovine heparin in United States will create new opportunities for manufacturers of heparin, crude heparin suppliers to make strides in this market.
On the other hand, risks and harmful side effects from porcine heparin, stringent regulatory scenario in some geographical areas and are some of the challenges faced by Heparin market.

Table of Content
MARKET OVERVIEW
1.1. Definitions
1.2. Research methodology
1.3. Market Segmentation
1.4. Assumptions
1.5. Limitations
2. EXECUTIVE SUMMARY
3. MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities
3.4. Premium industry trends
4. INDUSTRY ANALYSIS
4.1. Supply chain analysis
4.2. Pricing analysis (overall market)
4.3. Ecosystem analysis
4.3.1. Product analysis (quantitative benchmarking)
4.3.2. Application analysis (quantitative benchmarking)
4.3.3. Supplier Analysis(Suppliers of Crude Heparin, FDA guidance for Suppliers)
5. HEPARIN SEGMENTATION BY PRODUCT
5.1. Pricing segmentation
5.2. Market share segmentation
5.3. Revenue segmentation
5.4. Volume/shipment segmentation
5.5. Product
5.5.1. Unfractionated Heparin
5.5.2. Low Molecular Weight Heparin(LMWH)
5.5.3. Ultra Low Molecular Weight Heparin(ULMWH)
6. HEPARIN SEGMENTATION BY ROA(Root of Administration)
6.1. Pricing segmentation
6.2. Market share segmentation
6.3. Revenue segmentation
6.4. Volume/shipment segmentation
6.5. Types
6.5.1. IV Injection
6.5.2. Subcutaneous Injection
7. HEPARIN SEGMENTATION BY APPLICATION
7.1. Pricing segmentation
7.2. Market share segmentation
7.3. Revenue segmentation
7.4. Volume/shipment segmentation
7.4.1. Clinical Trials
7.4.2. Medical Devices
7.4.3. Blood Management
8. HEPARIN SEGMENTATION BY REGIONS
8.1. North America
8.1.1. Pricing segmentation
8.1.2. Market share segmentation
8.1.3. Revenue segmentation
8.1.4. Volume/shipment segmentation
8.1.5. Regulatory Scenario
8.2. APAC
8.2.1. Pricing segmentation
8.2.2. Market share segmentation
8.2.3. Revenue segmentation
8.2.4. Volume/shipment segmentation
8.2.5. Regulatory Scenario
8.3. Europe
8.3.1. Pricing segmentation
8.3.2. Market share segmentation
8.3.3. Revenue segmentation
8.3.4. Volume/shipment segmentation
8.3.5. Regulatory Scenario
8.4. South America
8.4.1. Pricing segmentation
8.4.2. Market share segmentation
8.4.3. Revenue segmentation
8.4.4. Volume/shipment segmentation
8.4.5. Regulatory Scenario
8.5. Middle East & Africa
8.5.1. Pricing segmentation
8.5.2. Market share segmentation
8.5.3. Revenue segmentation
8.5.4. Volume/shipment segmentation
8.5.5. Regulatory Scenario
9. COMPETITIVE LANDSCAPE
9.1. M&A
9.2. JV/Partnerships
10. KEY MARKET PLAYERS
10.1. Sanofi
10.2. LeoPharma
10.3. Pfizer
10.4. GlaxosmitheKline(GSK)
10.5. Baxter Healthcare
10.6. Fresnius Kabi AG
10.7. Teva Pharmaceuticals
10.8. Dr.Reddys Laboratories
10.9. Mylan N.V
11. KEY INNOVATORS
12. LAST WORD: SCALAR 360 DEGREE MARKET PERSPECTIVE